Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538846 | 0.88 | ACE (0.49) | CTSLCTSBSLC7A5 | |
| SCHEMBL30538864 | 0.88 | ACE (0.49) | CTSLCTSBSLC7A5 | |
| SCHEMBL30918343 | 0.86 | BACE1 (0.46) | CYP3A4CTSLCTSBGPR132 | |
| SCHEMBL29376211 | 0.86 | CTSL (0.44) | CYP3A4CTSLCTSBSCN9A | |
| SCHEMBL29375944 | 0.85 | NAALAD2 (0.51) | GPR132 | |
| SCHEMBL30788677 | 0.84 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL31614454 | 0.82 | CTSL (0.39) | CYP3A4CTSLCTSBSCN9A | |
| SCHEMBL4198783 | 0.81 | GPR132 (0.52) | GPR132 | |
| SCHEMBL27041689 | 0.81 | FOLH1 (0.48) | GPR132 | |
| SCHEMBL27041687 | 0.81 | FOLH1 (0.48) | GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| US-20230044268-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LIRAGLUTIDE | SHILPA MEDICARE LTD (IN) | 2023-02-09 | — | — | US | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20230044268-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LIRAGLUTIDE | SHILPA MEDICARE LTD (IN) | 2023-02-09 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | CYP3A4 528/4885CTSL 1131/4885CTSB 1321/4885 |
| US-20230044268-A1 | AN IMPROVED PROCESS FOR PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, GCG | CYP3A4 469/4885CTSL 747/4885CTSB 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.